Interim analysis of a phase 4 open-label trial in 181 mothers: maternal RSVpreF vaccine, infant nirsevimab, or both were safe with no related serious adverse events, and gave high infant RSV neutralising antibody levels through interim follow-up.
RCTn = 181 mothers
Rostad et al. Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial